Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Recruitment Status
COMPLETED - HAS RESULTS
(See Contacts and Locations)Verified November 2022 by Otonomy, Inc.
Sponsor
Otonomy, Inc.
Information Provided by (Responsible Party)
Otonomy, Inc.
Clinicaltrials.gov Identifier
NCT02612337
Other Study ID Numbers:
104-201506
First Submitted
November 17, 2015
First Posted
November 22, 2015
Results First Posted
October 23, 2022
Last Update Posted
January 11, 2023
Last Verified
November 2022

ClinicalTrials.gov processed this data on December 2022. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Meniere's Disease
Drug: OTO-104Drug: Placebo

Study Design

Study TypeInterventional
Actual Enrollment166 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingTriple
Primary PurposeTreatment
Official TitleA Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Study Start DateOctober 26, 2015
Actual Primary Completion DateJuly 17, 2017
Actual Study Completion DateJuly 17, 2017

Groups and Cohorts

Group/CohortIntervention/Treatment
OTO-104
12 mg dexamethasone
Drug: OTO-104
Single intratympanic injection of 12 mg OTO-104
Placebo
Drug: Placebo
Single intratympanic injection of placebo

Outcome Measures

Primary Outcome Measures
  1. The Number of DVD at Week 12 (Defined as the 4-week [28 Days] Interval From Week 9 Through Week 12).
    The number of DVDs at Week 12 (defined as the 4-week \[28 days\] interval from Week 9 through Week 12) was compared between OTO-104 and placebo. Week 12 = 12 weeks after dosing at the Baseline visit. Baseline occurred at the end of lead-in and no intervention was administered during lead-in.
Secondary Outcome Measures
  1. Effect of Vertigo on Daily Activities - Number of Days Sick at Home or Bedridden at Week 12 (Month 3)
    Questionnaire - subjects were instructed to record the effect on their daily activities of their total vertigo experienced that day using a 5-point scoring system: 0 = normal activity 1. = slight limitation 2. = moderate limitation 3. = sick at home 4. = bed ridden
  2. Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3)
    Otoscopic examinations were conducted at each visit. It was considered important to understand if the tympanic perforation that resulted from the IT injection at the Baseline visit persisted at the end of study visit (Week 12 \[Month 3\]).
  3. Audiometry - Shift in Air-Bone Gap at 500 Hz From Baseline to Week 12 (Month 3)
    The number of subjects with a change in air-bone gap from Baseline to Week 12 (Month 3) from no impairment at baseline (\<= 10 dB) to impairment at Month 3 (\>10 dB) when measured at 500 Hz.
  4. Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3)
    The number of subjects with a change in air-bone gap from Baseline to Week 12 (Month 3) from no impairment at baseline (\<= 10 dB) to impairment at Month 3 (\>10 dB) when measured at 1000 Hz.
  5. Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3)
    The number of subjects with a change in air-bone gap from Baseline to Week 12 (Month 3) from no impairment at baseline (\<= 10 dB) to impairment at Month 3 (\>10 dB) when measured at 2000 Hz.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Inclusion Criteria includes, but is not limited to:
Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology - Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study lead-in period.
Subject has experienced active vertigo during the lead-in period.
Subject has documented asymmetric sensorineural hearing loss.
Subject agrees to maintain their current treatments for Meniere's disease while on-study.
Exclusion Criteria
Inclusion Criteria includes, but is not limited to:
Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology - Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study lead-in period.
Subject has experienced active vertigo during the lead-in period.
Subject has documented asymmetric sensorineural hearing loss.
Subject agrees to maintain their current treatments for Meniere's disease while on-study. Exclusion Criteria includes, but is not limited to:
Subject is pregnant or lactating.
Subject has a history of immunodeficiency disease.
Subject has a history of previous endolymphatic sac surgery.
Subject has a history of previous use of intratympanic (IT) gentamicin in the affected ear.
Subject has a history of tympanostomy tubes with evidence of perforation or lack of closure.
Subject has experienced an adverse reaction to IT injection of steroids.
Subject has used an investigational drug or device in the 3 months prior to screening.
Subject has previously been randomized to a trial of OTO-104.

Contacts and Locations

Sponsors and CollaboratorsOtonomy, Inc.
Locations
Many sites in US. Refer to the contact info listed below. | San Diego California, United States,
Investigators
Study Chair: Kathie Bishop, PhD, Otonomy, Inc.
Study Documents (Full Text)
Documents provided by Otonomy, Inc.: Study Protocol and Statistical Analysis Plan  February 21, 2016